Peripheral T-Cell Lymphoma (PTCL) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Peripheral T-Cell Lymphoma (PTCL) Emerging Therapy and TPP Insights

Thelansis's "Peripheral T-Cell Lymphoma (PTCL) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Peripheral T-Cell Lymphoma (PTCL) Overview

Peripheral T-cell lymphoma (PTCL) represents a rare, heterogeneous, and highly aggressive group of mature T-cell and natural killer (NK)-cell neoplasms, accounting for approximately 10-15% of all non-Hodgkin lymphomas. The disease comprises multiple biologically distinct subtypes, most commonly PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL), each driven by epigenetic alterations, aberrant T-cell receptor signaling, and oncogenic mutations.

Clinically, PTCL is characterized by rapid disease progression, presenting with generalized lymphadenopathy, systemic B symptoms (fever, night sweats, weight loss), and frequent extranodal involvement, including the skin, bone marrow, and liver. The disease course is typically aggressive, with poor prognosis compared to B-cell lymphomas.

Historically, frontline treatment with CHOP-based chemotherapy resulted in suboptimal outcomes and high relapse rates due to intrinsic chemoresistance. The treatment paradigm has since evolved, particularly with the incorporation of targeted therapies. For CD30-positive subtypes (notably ALCL), the combination of brentuximab vedotin with chemotherapy (BV-CHP) has become a preferred frontline regimen.

Consolidation with autologous stem cell transplantation (ASCT) is commonly pursued in eligible patients achieving remission. In the relapsed/refractory setting, treatment relies on novel targeted agents, including histone deacetylase (HDAC) inhibitors and antifolate therapies such as pralatrexate. Despite these advances, outcomes remain limited, underscoring a significant unmet need for more effective and durable therapies.

Key Highlights

• In France, diagnosed incident PTCL cases are projected to increase from 1,448 to 1,981, indicating a rising disease burden.
• PTCL remains a rare but highly aggressive lymphoma subtype with poor prognosis compared to B-cell lymphomas.
• High relapse rates persist due to intrinsic resistance to conventional chemotherapy.
• Treatment paradigm is shifting toward targeted therapies (e.g., brentuximab vedotin) and precision medicine approaches.
• Significant unmet need exists in relapsed/refractory PTCL and long-term disease control.

Market Overview

• The France PTCL market is projected to grow from $21M to $32M, reflecting moderate market expansion.
• Market growth is driven by:
• Adoption of targeted therapies and antibody-drug conjugates
• Increasing use of transplant and second-line treatment strategies
• Despite low patient numbers, market value is supported by high-cost therapies and intensive treatment approaches.
• Continued innovation in epigenetic therapies and novel immuno-oncology agents is expected to shape future market dynamics.
• Future growth will depend on effective therapies for relapsed/refractory patients and improved survival outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Xenothera SAS
• Dizal Pharmaceuticals
• Chipscreen Biosciences, Ltd.
• Boryung Pharmaceutical Co., Ltd
• SecuraBio
• Acrotech Biopharma Inc.
• Boston Immune Technologies and Therapeutics
• Corvus Pharmaceuticals, Inc.
• SciTech Development, Inc.
• Aileron Therapeutics, Inc.
• AstraZeneca
• Kymera Therapeutics, Inc.
• Bio-Path Holdings, Inc.
• Pfizer